TPExtreme randomized trial: TPEx versus Extreme regimen in 1st line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

被引：57

作者：

Guigay, Joel

Fayette, Jerome

Mesia, Ricard

Lafond, Cedrik

Saada-Bouzid, Esma

Geoffrois, Lionnel

Martin, Laurent

Cupissol, Didier

Capitain, Olivier

Castanie, Helene

Vansteene, Damien

Schafhausen, Philippe

Arvis, Catherine Dubos

Even, Caroline

Sire, Christian

Delhommeau, Melissa

Michel, Cecile

Bourhis, Jean

Keilholz, Ulrich

Auperin, Anne

机构：

[1] Univ Cote Azur, Antoine Lacassagne Comprehens Canc Ctr, FHU OncoAge, Dept Med Oncol, Nice, France

[2] Ctr Leon Berard, Med Oncol, Lyon, France

[3] Catalan Inst Oncol, IDIBELL, Barcelona, Spain

[4] Clin Victor Hugo, Le Mans, France

[5] Univ Cote Azur, Ctr Antoine Lacassagne, Nice, France

[6] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France

[7] Clin Ormeaux, Le Havre, France

[8] Inst Canc Montpellier, Montpellier, France

[9] Inst Cancerol Ouest, Site Paul Papin, Angers, France

[10] Hop Prive Confluent SAS, Nantes, France

[11] Inst Cancerol Ouest Rene Gauducheau, Nantes, France

[12] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany

[13] Ctr Francois Baclesse, Oncol, Caen, France

[14] Gustave Roussy, Villejuif, France

[15] Grp Hosp Bretagne Sud Radiotherapie Oncol, Lorient, France

[16] GORTEC, Tours, France

[17] Charite Comprehens Canc Ctr, Berlin, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.6002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6002

引用

页数：2